Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
Montreal (Marketwire) - Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate. Adva-27a is a small molecule that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR) in vitro. The newly synthesized material which the Company took delivery of recently has been used to initiate several IND-Enabling experiments which are currently in progress. Some of these experiments include physical characterization of the molecule as well as various biological activity assays including protein binding, enzyme inhibition, cytotoxicity, in vivo clearance and xenograft studies in mice. The results of the IND-Enabling studies constitute an integral part of an IND Application (Investigational New Drug Application) which the Company must file with the regulatory authorities in the US and Canada as part of the drug development and approval process.
"This is a major milestone in our development of Adva-27a," said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "We are very excited to be at this point, the last step before Phase I clinical trials," he added.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
SOURCE: Sunshine Biopharma Inc.